Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly

Clinical Endocrinology

Volumn 69, Issue 2, 2008, Pages 299-305

  Chanson, Philippe ^a,b   Borson Chazot, Françoise ^c   Kuhn, Jean Marc ^d   Blumberg, Joëlle ^e   Maisonobe, Pascal ^e   Delemer, Brigitte ^f   Archambeaud, F ^g   Arlot, S ^g   Bringer, J ^g   Caron, P ^g   Estour, B ^g   Lorcy, Y ^g   Mahoudeau, J ^g   Rohmer, V ^g   Sadoul, J L ^g   Schlienger, J L ^g   Roger, P ^g   Verges, B ^g   Gaillard, R ^g  

^a BICÊTRE HOSPITAL   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c HÔPITAL NEUROLOGIQUE   (France)

^d INSERM   (France)

^e IPSEN   (France)

^f HÔPITAL MAISON BLANCHE   (France)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE; LANREOTIDE AUTOGEL; SOMATOMEDIN C;

ABDOMINAL PAIN; ACROMEGALY; ADULT; AGED; ARM SWELLING; ARTHRALGIA; ARTICLE; CHOLANGITIS; CHOLELITHIASIS; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; DIARRHEA; DOSE CALCULATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GALLBLADDER SLUDGE; GALLSTONE; GEL; HEADACHE; HUMAN; HYPERHIDROSIS; HYPOGLYCEMIA; INJECTION SITE PAIN; LEG SWELLING; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOPHLEBITIS; TREATMENT DURATION; TREATMENT OUTCOME;

ACROMEGALY; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; FEMALE; GELS; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; SOMATOSTATIN; TIME FACTORS; TITRIMETRY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 41349117707     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2008.03208.x     Document Type: Article

References (36)

1. Melmed, S., Casanueva, F., Cavagnini, F., Chanson, P., Frohman, L.A., Gaillard, R., Ghigo, E., Ho, K., Jaquet, P., Kleinberg, D., Lamberts, S., Laws, E., Lombardi, G., Sheppard, M.C., Thorner, M., Vance, M.L., Wass, J.A. Giustina, A. (2005) Consensus statement: medical management of acromegaly. European Journal of Endocrinology, 153, 737 740.
2. Colao, A., Ferone, D., Marzullo, P. Lombardi, G. (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocrine Reviews, 25, 102 152.
3. Holdaway, I.M., Rajasoorya, C. Gamble, G.D. (2004) Factors influencing mortality in acromegaly. Journal of Clinical Endocrinology and Metabolism, 89, 667 674.
4. Melmed, S. (2006) Medical progress: acromegaly. New England Journal of Medicine, 355, 2558 2573.
5. Caron, P., Cogne, M., Raingeard, I., Bex-Bachellerie, V. Kuhn, J.M. (2006) Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly. Clinical Endocrinology, 64, 209 214.
6. Cozzi, R., Montini, M., Attanasio, R., Albizzi, M., Lasio, G., Lodrini, S., Doneda, P., Cortesi, L. Pagani, G. (2006) Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. Journal of Clinical Endocrinology and Metabolism, 91, 1397 1403.
7. Freda, P.U. (2002) Somatostatin analogs in acromegaly. Journal of Clinical Endocrinology and Metabolism, 87, 3013 3018.
8. Caron, P., Beckers, A., Cullen, D.R., Goth, M.I., Gutt, B., Laurberg, P., Pico, A.M., Valimaki, M. Zgliczynski, W. (2002) Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. Journal of Clinical Endocrinology and Metabolism, 87, 99 104.
9. Caron, P., Bex, M., Cullen, D.R., Feldt-Rasmussen, U., Pico Alfonso, A.M., Pynka, S., Racz, K., Schopohl, J., Tabarin, A. Valimaki, M.J. (2004) One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel. Clinical Endocrinology, 60, 734 740.
10. Ashwell, S.G., Bevan, J.S., Edwards, O.M., Harris, M.M., Holmes, C., Middleton, M.A. James, R.A. (2004) The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR. European Journal of Endocrinology, 150, 473 480.
11. Alexopoulou, O., Abrams, P., Verhelst, J., Poppe, K., Velkeniers, B., Abs, R. Maiter, D. (2004) Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. European Journal of Endocrinology, 151, 317 324.
12. van Thiel, S.W., Romijn, J.A., Biermasz, N.R., Ballieux, B.E., Frolich, M., Smit, J.W., Corssmit, E.P., Roelfsema, F. Pereira, A.M. (2004) Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. European Journal of Endocrinology, 150, 489 495.
13. Trainer, P.J., Drake, W.M., Katznelson, L., Freda, P.U., Herman-Bonert, V., van der Lely, A.J., Dimaraki, E.V., Stewart, P.M., Friend, K.E., Vance, M.L., Besser, G.M., Scarlett, J.A., Thorner, M.O., Parkinson, C., Klibanski, A., Powell, J.S., Barkan, A.L., Sheppard, M.C., Malsonado, M., Rose, D.R., Clemmons, D.R., Johannsson, G., Bengtsson, B.A., Stavrou, S., Kleinberg, D.L., Cook, D.M., Phillips, L.S., Bidlingmaier, M., Strasburger, C.J., Hackett, S., Zib, K., Bennett, W.F. Davis, R.J. (2000) Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. New England Journal of Medicine, 342, 1171 1177.
14. van der Lely, A.J., Hutson, R.K., Trainer, P.J., Besser, G.M., Barkan, A.L., Katznelson, L., Klibanski, A., Herman-Bonert, V., Melmed, S., Vance, M.L., Freda, P.U., Stewart, P.M., Friend, K.E., Clemmons, D.R., Johannsson, G., Stavrou, S., Cook, D.M., Phillips, L.S., Strasburger, C.J., Hackett, S., Zib, K.A., Davis, R.J., Scarlett, J.A. Thorner, M.O. (2001) Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet, 358, 1754 1759.
15. Freda, P.U., Katznelson, L., van der Lely, A.J., Reyes, C.M., Zhao, S. Rabinowitz, D. (2005) Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. Journal of Clinical Endocrinology and Metabolism, 90, 4465 4473.
16. Giustina, A., Barkan, A., Casanueva, F.F., Cavagnini, F., Frohman, L., Ho, K., Veldhuis, J., Wass, J., Von Werder, K. Melmed, S. (2000) Criteria for cure of acromegaly: a consensus statement. Journal of Clinical Endocrinology and Metabolism, 85, 526 529.
17. Cozzi, R., Attanasio, R., Montini, M., Pagani, G., Lasio, G., Lodrini, S., Barausse, M., Albizzi, M., Dallabonzana, D. Pedroncelli, A.M. (2003) Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? Journal of Clinical Endocrinology and Metabolism, 88, 3090 3098.
18. Freda, P.U., Nuruzzaman, A.T., Reyes, C.M., Sundeen, R.E. Post, K.D. (2004) Significance of 'abnormal' nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. Journal of Clinical Endocrinology and Metabolism, 89, 495 500.
19. Jehle, S., Reyes, C.M., Sundeen, R.E. Freda, P.U. (2005) Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism, 90, 1588 1593.
20. Mukherjee, A., Monson, J.P., Jonsson, P.J., Trainer, P.J. Shalet, S.M. (2003) Seeking the optimal target range for insulin-like growth factor I during the treatment of adult growth hormone disorders. Journal of Clinical Endocrinology and Metabolism, 88, 5865 5870.
21. Puder, J.J., Nilavar, S., Post, K.D. Freda, P.U. (2005) Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism, 90, 1972 1978.
22. Swearingen, B., Barker, F.G., 2nd., Katznelson, L., Biller, B.M., Grinspoon, S., Klibanski, A., Moayeri, N., Black, P.M. Zervas, N.T. (1998) Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. Journal of Clinical Endocrinology and Metabolism, 83, 3419 3426.
23. Kauppinen-Makelin, R., Sane, T., Reunanen, A., Valimaki, M.J., Niskanen, L., Markkanen, H., Loyttyniemi, E., Ebeling, T., Jaatinen, P., Laine, H., Nuutila, P., Salmela, P., Salmi, J., Stenman, U.H., Viikari, J. Voutilainen, E. (2005) A nationwide survey of mortality in acromegaly. Journal of Clinical Endocrinology and Metabolism, 90, 4081 4086.
24. Ayuk, J., Clayton, R.N., Holder, G., Sheppard, M.C., Stewart, P.M. Bates, A.S. (2004) Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism, 89, 1613 1617.
25. Bonapart, I.E., van Domburg, R., ten Have, S.M., de Herder, W.W., Erdman, R.A., Janssen, J.A. van der Lely, A.J. (2005) The 'bio-assay' quality of life might be a better marker of disease activity in acromegalic patients than serum total IGF-I concentrations. European Journal of Endocrinology, 152, 217 224.
26. Wass, J.A. (1997) Growth hormone, insulin-like growth factor-I and its binding proteins in the follow-up of acromegaly. Journal of Endocrinology, 155 (Suppl. 1 17 19.
27. Freda, P.U., Post, K.D., Powell, J.S. Wardlow, S.L. (1998) Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. Journal of Clinical Endocrinology and Metabolism, 83, 3808 3816.
28. Trainer, P.J. (2002) Editorial: acromegaly - consensus, what consensus? Journal of Clinical Endocrinology and Metabolism, 87, 3534 3536.
29. Biermasz, N.R., Pereira, A.M., Frölich, M., Romijin, J.A., Veldhuis, J.D. Roelfsema, F. (2004) Octreotide represses secretory-burst mass and nonpulsatile secretion but does not restore event frequency or orderly GH secretion in acromegaly. American Journal of Physiology - Endocrinology and Metabolism, 286, 25 30.
30. Grottoli, S., Celleno, R., Gasco, V., Pivonello, R., Caramella, D., Barreca, A., Ragazzoni, F., Pigliaru, F., Alberti, D., Ferrara, R. Angeletti, G. (2005) Efficacy and safety of 48 weeks of treatment with octreotide LAR in newly diagnosed acromegalic patients with macroadenomas: an open-label, multicenter, non-comparative study. Journal of Endocrinological Investigation, 28, 978 983.
31. Murray, R.D., Kim, K., Ren, S.G., Chelly, M., Umehara, Y. Melmed, S. (2004) Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis. Journal of Clinical Investigation, 114, 349 356.
32. Hofland, L.J. Lamberts, S.W. (2003) The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocrine Reviews, 24, 28 47.
33. James, R.A. Gilroy, T. (2001) Dose and frequency titration of somatostatin analogues in the treatment of acromegaly - an injection of expediency. Clinical Endocrinology, 54, 11 13.
34. Jenkins, P.J., Akker, S., Chew, S.L., Besser, G.M., Monson, J.P. Grossman, A.B. (2000) Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration. Clinical Endocrinology, 53, 719 724.
35. Lucas, T. Astorga, R. (2006) Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles, 30 mg: a phase III trial. Clinical Endocrinology, 65, 320 326.
36. Ronchi, C.L., Boschetti, M., Degli Uberti, E.C., Mariotti, S., Grottoli, S., Loli, P., Lombardi, G., Tamburrano, G., Arvigo, M., Angeletti, G., Boscani, P.F., Beck-Peccoz, P. Arosio, M. (2007) Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study. Clinical Endocrinology, 67, 512 519.